GlobalData on MSN2d
MSD commences Phase III trial of DLBCL treatment
MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...
verywellhealth3d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer Type
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Contract Pharma3d
Bio-Rad Launches Dye Label Kits for Antibody Conjugation
New kits are designed to offer a convenient method to label any antibody with one of Bio-Rad’s StarBright Dyes.
FierceBiotech3d
Pfizer builds out oncology team with appointment of Novartis vet Jeff Legos
In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...
GlobalData on MSN3d
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...
Asia News Network3d
Brunei introduces pneumococcal vaccine for infants, children
With this addition, the Sultanate's immunisation programme now includes 12 vaccines to prevent 12 vaccine-preventable diseases. Vaccinations under the programme are provided free of charge at Maternal ...
中国日报网4d
Scientists synthesize high-conductivity 2D conducting polymers
BEIJING -- An international team of researchers has synthesized a multilayer-stacked two-dimensional polyaniline crystal, ...
FiercePharma4d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 ...
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31
Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 ...